Literature DB >> 35099593

A novel SPTB mutation causes hereditary spherocytosis via loss-of-function of β-spectrin.

Shan Li1, Ping Guo2, Leyuan Mi1,3, Xiaojing Chai4, Kewang Xi1, Ting Liu1, Li Lu4, Juan Li5.   

Abstract

Hereditary spherocytosis (HS) is the most frequently observed chronic non-immune hemolytic disorder caused by altered red cell membrane function. SPTB gene mutation is one of the most common causes of HS, but pathogenicity analyses and pathogenesis research on these mutations have not been widely conducted. In this study, a novel heterozygous mutation of the SPTB gene (c.1509_1518del; p.K503Nfs*67) was identified in a Chinese family with HS by whole-exome sequencing (WES) and was then confirmed by Sanger sequencing. Next, the pathogenicity and pathogenesis of this mutation were studied using peripheral blood. We found that this mutation disrupted the synthesis and localization of β-spectrin and weakened the interaction between β-spectrin and ankyrin, which may be caused by the nonsense-mediated mRNA degradation pathway. These changes lead to the transformation of discoid erythrocytes into spherocytes, resulting in hemolytic anemia. Therefore, we classified this novel mutation as a pathogenic mutation leading to loss-of-function of β-spectrin. It would be insightful to perform the same mutation test and to provide genetic counseling to other relatives of the proband. Our study increases the current understanding of the molecular mechanisms related to mutations in SPTB.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Ankyrin; Hereditary spherocytosis; SPTB; WES; β-spectrin

Mesh:

Substances:

Year:  2022        PMID: 35099593     DOI: 10.1007/s00277-022-04773-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  28 in total

Review 1.  The molecular basis of hereditary red cell membrane disorders.

Authors:  Jean Delaunay
Journal:  Blood Rev       Date:  2006-05-30       Impact factor: 8.250

Review 2.  Hereditary red cell membrane defects: diagnostic and clinical aspects.

Authors:  Wilma Barcellini; Paola Bianchi; Elisa Fermo; Francesca G Imperiali; Anna P Marcello; Cristina Vercellati; Anna Zaninoni; Alberto Zanella
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

3.  A systematic review of hereditary spherocytosis reported in Chinese biomedical journals from 1978 to 2013 and estimation of the prevalence of the disease using a disease model.

Authors:  Chao Wang; Yazhou Cui; Yan Li; Xiao Liu; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2015-05

Review 4.  Red cell membrane disorders.

Authors:  J Narla; N Mohandas
Journal:  Int J Lab Hematol       Date:  2017-05       Impact factor: 2.877

5.  Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update.

Authors:  Paula H B Bolton-Maggs; Jacob C Langer; Achille Iolascon; Paul Tittensor; May-Jean King
Journal:  Br J Haematol       Date:  2011-11-05       Impact factor: 6.998

Review 6.  Red cell membrane: past, present, and future.

Authors:  Narla Mohandas; Patrick G Gallagher
Journal:  Blood       Date:  2008-11-15       Impact factor: 22.113

Review 7.  Disorders of red cell membrane.

Authors:  Xiuli An; Narla Mohandas
Journal:  Br J Haematol       Date:  2008-03-12       Impact factor: 6.998

8.  Hereditary spherocytosis.

Authors:  Silverio Perrotta; Patrick G Gallagher; Narla Mohandas
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

9.  Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias.

Authors:  Archana M Agarwal; Roberto H Nussenzveig; Noel S Reading; Jay L Patel; Nikhil Sangle; Mohamed E Salama; Josef T Prchal; Sherrie L Perkins; Hassan M Yaish; Robert D Christensen
Journal:  Br J Haematol       Date:  2016-06-12       Impact factor: 6.998

Review 10.  Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders.

Authors:  Lydie Da Costa; Julie Galimand; Odile Fenneteau; Narla Mohandas
Journal:  Blood Rev       Date:  2013-05-09       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.